Literature DB >> 32240614

Long non-coding RNA ROR sponges miR-138 to aggravate hypoxia/reoxygenation-induced cardiomyocyte apoptosis via upregulating Mst1.

Yan-Hui Hu1, Jing Sun1, Jing Zhang1, Fu-Zhou Hua1, Qin Liu1, Ying-Ping Liang2.   

Abstract

BACKGROUND: Hypoxia/reoxygenation (H/R) injury of cardiomyocytes causes an irreversible damage to heart and largely results in acute myocardial infarction. Study has indicated lncRNA ROR aggravates myocardial ischemia/reperfusion (I/R) injury. Also, lncRNA ROR sponges miR-138 to promote osteogenesis. MiR-138 involves in hypoxic pulmonary vascular remodelling by targeting Mst1. However, the interaction between lncRNA ROR, miR-138 and Mst1 involved in myocardial H/R injury is still unknown.
METHODS: H9C2 cells were used to establish H/R injury model. The expression levels of lncRNA ROR and miR-138 were modified by transfection with the miR-138 mimics or lncRNA ROR overexpression plasmid. MTT and flow cytometry analysis were performed to detect cell proliferation and apoptosis. Dual luciferase reporter assay was used to determine interaction between lncRNA ROR and miR-138 or miR-138 and Mst1. Expression levels of lncRNA ROR, miR-138, Mst1 and apoptosis-related markers were determined by qRT-PCR or western blotting.
RESULTS: LncRNA ROR was significantly up-regulated, while miR-138 was obviously down-regulated in H/R-induced injury of H9C2 cells. Furthermore, miR-138 overexpression alleviated cardiac cell apoptosis induced by H/R injury. Mst1 was revealed to be a target of miR-138 and negatively regulated by miR-138. Mst1 overexpression reversed the protective effects of miR-138 on H/R injury of H9C2 cells. LncRNA ROR was identified as a sponge for miR-138. MiR-138 could protect H9C2 cells form H/R injury induced by lncRNA ROR overexpression.
CONCLUSION: Our study provides that lncRNA ROR sponges miR-138 to aggravate H/R-induced myocardial cell injury by upregulating the expression of Mst1.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; H9C2 cells; Hypoxia/reoxygenation; LncRNA ROR; MiR-138; Mst1

Year:  2020        PMID: 32240614     DOI: 10.1016/j.yexmp.2020.104430

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  6 in total

1.  Knockout of circRNA single stranded interacting protein 1 (circRBMS1) played a protective role in myocardial ischemia-reperfusion injury though inhibition of miR-2355-3p/Mammalian Sterile20-like kinase 1 (MST1) axis.

Authors:  Yingping Liang; Huanhuan Jie; Qin Liu; Chang Li; Renjie Xiao; Xianliang Xing; Jing Sun; Shuchun Yu; Yanhui Hu; Guo-Hai Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Dexmedetomidine protects H9C2 rat cardiomyocytes against hypoxia/reoxygenation injury by regulating the long non-coding RNA colon cancer-associated transcript 1/microRNA-8063/Wnt/β-catenin axis.

Authors:  Chundong Liu; Rui Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Cardioprotective Effect of circ_SMG6 Knockdown against Myocardial Ischemia/Reperfusion Injury Correlates with miR-138-5p-Mediated EGR1/TLR4/TRIF Inactivation.

Authors:  Chen Huang; Yalun Qu; Fan Feng; Hualu Zhang; Liliang Shu; Xiaohua Zhu; Gongcheng Huang; Jing Xu
Journal:  Oxid Med Cell Longev       Date:  2022-01-27       Impact factor: 6.543

4.  CircSAMD4A aggravates H/R-induced cardiomyocyte apoptosis and inflammatory response by sponging miR-138-5p.

Authors:  Xiaorong Hu; Ruisong Ma; Jianlei Cao; Xianjin Du; Xinyong Cai; Yongzhen Fan
Journal:  J Cell Mol Med       Date:  2020-11-21       Impact factor: 5.310

5.  Upregulation of LINC01503 promotes cervical cancer progression by targeting the miR-615-3p/CCND1 axis.

Authors:  Jing Feng; Fang-Yuan Gao; Yan-Ying Li; Xi-Yun Xiao; Jie Xi
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

6.  Relationships between Indicators of Lower Extremity Artery Disease and miRNA Expression in Peripheral Blood Mononuclear Cells.

Authors:  Daniel P Zalewski; Karol P Ruszel; Andrzej Stępniewski; Dariusz Gałkowski; Marcin Feldo; Janusz Kocki; Anna Bogucka-Kocka
Journal:  J Clin Med       Date:  2022-03-15       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.